secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001628280-26-010376
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Pharmaceuticals receives FDA approval for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia
--------------------------------------------------------------------------------

- Bysanti (milsaperidone) approved for acute manic/mixed episodes of bipolar I disorder and schizophrenia in adults.
- Bysanti is a new chemical entity that interconverts to iloperidone, leveraging 100,000+ patient-years of real-world experience.
- Vanda expects commercial availability in Q3 2026; marketing exclusivity protected by patents expiring in 2044.
- This is Vanda's second new drug approval in less than 2 months, following NEREUS in December 2025.
- Bysanti is being tested as a once-daily adjunctive for treatment-resistant major depressive disorder, study completion expected by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026010376/0001628280-26-010376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026010376/vnda-20260220.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-010376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer